经济观察网泰恩康（301263）2026年将有多项关键事件值得关注，涉及公司治理、产品管线及市场动 态。 公司多个仿制药和创新药预计在2026年取得重要进展。复方硫酸钠片(国内首仿)与和胃整肠丸(国内独 家)的本地化生产注册均预计在2026年上半年获批。老花眼用药盐酸毛果芸香碱滴眼液(国内首仿)预计在 2026年下半年获批。此外，创新药CKBA乳膏针对儿童白癜风的II期临床试验计划于2026年第一季度启 动首例患者入组，并计划同期向FDA申报。 股票近期走势 2026年1月28日，公司发布《2026年员工持股计划(草案)》，拟向不超过145名员工实施股权激励，并设 定了2026年至2028年的业绩考核目标。其中，2026年营业收入目标值为10.00亿元，考核利润目标值为 3.00亿元。 产品研发进展 公司于2025年12月15日被纳入中证1000指数拟生效样本范围，市场预期其有望被纳入相关ETF的被动配 置范畴，可能对股票流动性产生长期影响。2026年2月2日，公司控股股东郑汉杰和孙伟文部分股份质 押，合计质押股份占公司总股本的13.81%，公告称此举为个人资金需要。2026年2月13日，泰恩康股价 上涨2. ...

Core Insights - The article highlights the recent institutional investor research activities involving 113 listed companies, with notable stock performance from companies like Kewen Technology and Hason Co., which saw increases exceeding 30% [3]. Group 1: Shanghai Bank - Shanghai Bank received the highest number of institutional investor visits last week, with 75 institutions participating, focusing on the bank's credit deployment plans for the new year [5]. - The bank's management indicated an improvement in the quantity and quality of its "New Year Red" credit projects, particularly in retail credit, emphasizing housing and automotive sectors [5]. - The bank anticipates a slight decline in net interest margin due to expected decreases in both loan and deposit pricing, influenced by market competition and the ongoing repricing of existing assets [5]. Group 2: Tainkang - Tainkang was visited by 57 institutional investors, with a focus on its upcoming product approvals and commercialization strategies [7]. - The company announced significant revenue targets for 2026-2028, aiming for 1 billion, 1.5 billion, and 2 billion respectively, with profit targets of 300 million, 500 million, and 800 million [7][8]. - Tainkang plans to leverage existing products and new approvals to achieve substantial revenue growth, particularly with its unique formulations expected to dominate the market [8]. Group 3: Bee Assistant - Bee Assistant also received 57 institutional visits, with a focus on its developments in AI applications and commercial aerospace [8]. - The company is positioning itself in the aviation internet sector, aiming to enhance communication services and follow advancements in low-orbit satellite technology [8]. Group 4: ST Jingji - ST Jingji engaged with 48 institutional investors, reporting significant breakthroughs in the North American market as a core equipment supplier for photovoltaic components [10]. - The company is preparing for advancements in space photovoltaic technology, having made technical reserves in response to emerging opportunities in this field [10][11]. - ST Jingji emphasizes the importance of lightweight and flexible solar technology for space applications, aligning its R&D efforts with these requirements [11].

Core Viewpoint - The company, 泰恩康 (301263.SZ), is experiencing stable revenue from existing products while anticipating significant growth from upcoming core products expected to be approved or submitted for approval in the near future [1] Existing Products - The company’s current products, including the dual-purpose health medication "爱廷玖", ophthalmic drug "沃丽汀", and traditional Chinese medicine, are maintaining stable revenue [1] Upcoming Product Approvals - Multiple core products are expected to be approved or submitted for approval: - "爱廷列" Finasteride and Tadalafil compound capsule (first domestic generic) is expected to be approved by December 2025 - Lidocaine and Prilocaine aerosol (first domestic generic) has completed clinical trials, with registration expected to be accepted by the drug regulatory authority soon - Compound Sodium Sulfate tablets (first domestic generic) are anticipated to be approved in the first half of 2026 - "和胃整肠丸" (exclusive domestic) localization production registration is expected to be approved in the first half of 2026 - Pilocarpine eye drops for presbyopia (first domestic generic) are expected to be approved in the second half of 2026 [1] Revenue Growth Projections - With the approval and launch of the aforementioned core products, the company expects a significant increase in revenue from existing business segments in 2026, with explosive growth anticipated in 2027 and 2028 [1]

Group 1: Investor Relations Activity - The investor relations activity involved specific targeted research with participation from various fund management companies and securities firms [2][3]. - The meeting was held online on a Thursday morning, with a duration of 50 minutes [2]. Group 2: Employee Stock Ownership Plan - The company disclosed a draft for an employee stock ownership plan aiming to raise a total of CNY 33.608 million, involving directors, senior management, and core employees [3]. - The performance assessment period for the plan is set from 2026 to 2028, with specific revenue and profit targets: - Revenue targets: CNY 1 billion in 2026, CNY 1.5 billion in 2027, and CNY 2 billion in 2028 - Profit targets: CNY 300 million in 2026, CNY 500 million in 2027, and CNY 800 million in 2028 [3][4]. Group 3: Product Development and Market Strategy - The company has several core products expected to be approved or submitted for approval, including "Aitinglie" and "Lidocaine" aerosol, with anticipated revenue growth from existing products and new approvals [4][5]. - The company is actively promoting the "Hewei Zhengchang Wan" product through various media channels and expanding its sales through clinics and online platforms [5][8]. - The company plans to enhance brand promotion and has established a dedicated team for third-party channels, focusing on clinics and internet hospitals [8]. Group 4: Alzheimer's Disease Research - The company is developing CKBA for Alzheimer's disease, which has shown promising results in animal models, including cognitive improvement and reduced neuroinflammation [6][7]. - CKBA's mechanism targets MFE-2, a key enzyme in lipid metabolism, which is crucial for maintaining the homeostasis of microglial cells [7]. Group 5: Clinical Trials and Market Potential - The company is prioritizing the registration of treatments for pediatric vitiligo and rosacea, with rosacea expected to progress faster due to a shorter treatment cycle [9][10]. - The domestic market for pediatric vitiligo is significant, with no existing treatments approved by the FDA, indicating potential for market expansion [11]. Group 6: Forward-Looking Statements - The report includes forward-looking statements regarding future plans and performance forecasts, emphasizing the need for investors to recognize associated risks [11].

在产品管线方面，根据公司1月22日披露的公告显示，公司核心在研产品CKBA乳膏针对儿童白癜风的II 期临床试验申请已获得批准，前期探索性研究显示其联合光疗方案疗效显著，该II期试验计划于2026年 第一季度启动首例患者入组，并计划同期启动FDA临床申报。 与此同时，公司仿制药业务迎来收获期，根据公司2025年11月21日披露的投资者关系活动记录表显示， 公司复方硫酸钠片(国内首仿)与和胃整肠丸(国内独家)的本地化生产注册均预计在2026年上半年获批； 老花眼用药盐酸毛果芸香碱滴眼液(国内首仿)则预计在2026年下半年获批。 根据公告，本次员工持股计划的资金来源为员工合法薪酬及自筹资金，公司不存在向持有人提供财务资 助或为其贷款提供担保的情形。计划购买回购股份的价格为16.93元/股，拟持有的标的股票数量不超过 198.51万股，约占公司总股本的0.47%。 草案明确了2026年至2028年三个年度的业绩考核目标。2026年度，营业收入目标值为10.00亿元，触发 值为9.00亿元；考核利润目标值为3.00亿元，触发值为2.70亿元。2027年度，营业收入目标值提升至 15.00亿元，触发值为13.50亿元；考 ...

Group 1 - The core point of the news is that Guangdong Taiankang Pharmaceutical Co., Ltd. has disclosed its employee stock ownership plan for 2026, aiming to raise a maximum of 33.608 million yuan, with participation from up to 145 individuals including directors, senior management, and key employees [1] - The employee stock ownership plan is closely tied to the company's performance over the next three years, with assessment indicators including both "operating revenue" and "assessed profit," targeting significant growth [1][2] - The plan outlines specific unlock periods and performance targets, with the first unlock period set for 2026, requiring operating revenue to reach 1 billion yuan and assessed profit to hit 270 million yuan [2] Group 2 - The company is expected to see significant revenue growth as several core products are set to be approved or submitted for approval, including a domestic first generic of lidocaine and prilocaine aerosol, which is anticipated to complete registration by 2026 [2][3] - Participants in the employee stock ownership plan are required to use their own funds for subscription, with shares sourced from the company's repurchased stock at a price of 16.93 yuan per share [3] - The company believes that this long-term mechanism of employee stock ownership will effectively motivate the core team's enthusiasm and creativity, promoting the research, market promotion, and sales of core products to ensure the achievement of high growth targets [3]

Group 1: Clinical Research and Development - The company has initiated a Phase II clinical trial for CKBA cream for pediatric vitiligo, with the application accepted by the National Medical Products Administration in November 2025 [2][3]. - The exploratory study included 30 pediatric patients aged 2-12 years, showing a significant improvement in VASI scores with a 56.53% change in the treatment group compared to a 16.67% change in the control group (P=0.0029) [3]. - The Phase II clinical trial is expected to begin patient enrollment in Q2 2026, with a goal to complete it by mid-2027 [4]. Group 2: Market Potential and Demand - There are currently no approved drugs for pediatric vitiligo (ages 2-12) globally, indicating a significant unmet clinical need [5]. - The estimated market size for pediatric vitiligo treatment in China exceeds 100 billion CNY, with annual treatment costs ranging from 15,000 to 20,000 CNY per patient [6]. - CKBA is expected to achieve annual peak sales exceeding 5 billion CNY once approved for pediatric use [6]. Group 3: Additional Clinical Developments - The company has completed Phase II trials for CKBA in adult vitiligo and plans to optimize the Phase III trial protocol, with an application expected in Q1 2026 [7]. - CKBA is also being developed for other indications, including rosacea and Alzheimer's disease, with clinical trials for rosacea expected to start in Q1 2026 [7]. Group 4: Business Growth and Future Plans - The company anticipates significant revenue growth in 2026 and explosive growth in 2027, driven by the approval of several core products [8]. - Key products expected to be approved include a combination capsule of finasteride and tadalafil, and a lidocaine and prilocaine aerosol, among others [8].

Group 1: Clinical Trial Overview - The company has received approval from the National Medical Products Administration for a Phase II clinical trial of CKBA cream for treating vitiligo in children aged 2-12 years, with a total of 30 patients enrolled over a 24-week period [3][4]. - The study showed that the 1.5% CKBA cream combined with NB-UVB therapy resulted in a VASI score improvement of -56.53%, significantly better than the control group’s -16.67% (P=0.0029) [3][4]. - The exploratory study validated the effectiveness and safety of the CKBA cream in pediatric vitiligo patients, providing a basis for larger-scale trials [3][4]. Group 2: Market Potential and Demand - There are currently no approved drugs for pediatric vitiligo globally, with an estimated 30 million vitiligo patients in China, of which 32%-40% are children [4][5]. - The annual treatment cost for pediatric vitiligo is estimated at 15,000 to 20,000 CNY, suggesting a market potential exceeding 100 billion CNY [4][5]. - If approved, CKBA is projected to achieve annual sales exceeding 5 billion CNY in the pediatric vitiligo market [4][5]. Group 3: Competitive Landscape - CKBA is the first innovative drug in China to conduct Phase II clinical trials for children under 12 with vitiligo, with no existing approved treatments [5][6]. - The drug's unique mechanism as an immune modulator offers targeted treatment, making it safer and more suitable for children compared to traditional immunosuppressants [4][5]. Group 4: Future Development Plans - The company plans to submit an application for a Phase III clinical trial for adult vitiligo based on the successful completion of Phase II trials [5][6]. - There are ongoing preparations for a Phase II/III clinical trial for CKBA in treating rosacea, with an IND application for Alzheimer's disease planned for the second half of 2026 [6][9]. - The company anticipates significant revenue growth in 2026 and explosive growth in 2027 as new products are approved [10].

Core Viewpoint - 泰恩康, a well-known pharmaceutical company in China, is facing challenges in revenue and profit growth despite having a diverse product line and technical service capabilities [1][5]. Group 1: Business Overview - 泰恩康 was established on January 22, 1999, and went public on March 29, 2022, on the Shenzhen Stock Exchange, with its headquarters in Shantou, Guangdong Province [1]. - The company specializes in the agency operation, research and development, production, and sales of pharmaceutical products, medical devices, and health materials, along with providing pharmaceutical technology services and technology transfer [1]. Group 2: Financial Performance - For Q3 2025, 泰恩康 reported revenue of 526 million yuan, ranking 78th out of 110 in the industry, significantly lower than the top competitors, 华东医药 (32.664 billion yuan) and 复星医药 (29.393 billion yuan) [2]. - The net profit for the same period was 21.9682 million yuan, placing it 73rd in the industry, again trailing behind leading companies like 恒瑞医药 (5.76 billion yuan) and 复星医药 (3.056 billion yuan) [2]. Group 3: Financial Ratios - 泰恩康's debt-to-asset ratio stood at 24.84% in Q3 2025, an increase from 20.18% year-on-year, but still below the industry average of 35.26%, indicating better solvency compared to peers [3]. - The gross profit margin was reported at 55.61%, down from 61.41% year-on-year and below the industry average of 57.17%, reflecting challenges in profitability [3]. Group 4: Management and Shareholder Information - The chairman, 郑汉杰, received a salary of 437,100 yuan in 2024, a decrease of 50,100 yuan from the previous year [4]. - As of September 30, 2025, the number of A-share shareholders increased by 9.32% to 12,000, while the average number of circulating A-shares held per account decreased by 8.53% to 25,400 [5]. Group 5: Business Highlights and Future Outlook - Despite a decline in revenue and profit, 泰恩康 has several promising developments, including the upcoming clinical trials for CKBA for vitiligo and rosacea, and the orderly review of high-potential products like复方硫酸钠片 and 和胃整肠丸 [5]. - The company is projected to have earnings per share of 0.22, 0.48, and 0.85 yuan for 2025, 2026, and 2027 respectively, with a target price of 32.64 yuan based on a 68x P/E ratio for 2026 [5].

Investment Rating - The report maintains a "Buy" rating for the company [3][6]. Core Insights - The company is experiencing pressure on profitability, but progress on research and development (R&D) products is on track [2]. - Revenue for the first three quarters of 2025 was 526 million yuan, a year-on-year decrease of 8.1%, with a net profit attributable to the parent company of 31 million yuan, down 73.0% year-on-year [12]. - The company is expected to see a gradual recovery in revenue growth, with projections of 754 million yuan in 2025, 964 million yuan in 2026, and 1.308 billion yuan in 2027, reflecting growth rates of 4.6%, 27.8%, and 35.8% respectively [5][12]. Financial Forecasts - The earnings per share (EPS) for 2025, 2026, and 2027 are projected to be 0.22 yuan, 0.48 yuan, and 0.85 yuan respectively, revised down from previous estimates [3]. - The company’s gross margin is expected to improve from 57.0% in 2025 to 70.8% in 2027, while the net profit margin is projected to increase from 12.3% to 27.6% over the same period [5][12]. - The target price for the company is set at 32.64 yuan based on a price-to-earnings (P/E) ratio of 68 times for 2026 [3][6]. Clinical Development Progress - The company is set to initiate Phase III clinical trials for CKBA for vitiligo and Phase II/III trials for rosacea by the end of 2025 [12]. - Several high-potential products are progressing through the review process, with expectations for approvals either by the end of this year or next year [12].